Literature DB >> 16820007

Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.

G Sadri-Vakili1, A S Menon, L A Farrell, C E Keller-McGandy, I Cantuti-Castelvetri, D G Standaert, S J Augood, G J Yohrling, J-H J Cha.   

Abstract

Transcriptional dysregulation is a central pathogenic mechanism in Huntington's disease (HD); HD and transgenic mouse models of HD demonstrate down-regulation of specific genes at the level of mRNA expression. Furthermore, neuronal intranuclear inclusions (NIIs) have been identified in the brains of R6/2 mice and HD patients. One possibility is that NIIs contribute to transcriptional dysregulation by sequestering transcription factors. We therefore assessed the relationship between NIIs and transcriptional dysregulation in the R6/2 mouse, using double-label in situ hybridization combined with immunohistochemistry, and laser capture microdissection combined with quantitative real-time PCR. There was no difference in transcript levels of specific genes between NII-positive and NII-negative neurons. These results demonstrate that NIIs do not cause decreases in D2, PPE and PSS mRNA levels in R6/2 striatum and therefore are not involved in the down-regulation of these specific genes in this HD model. In addition, these observations argue against the notion that NIIs protect against transcriptional dysregulation in HD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820007     DOI: 10.1111/j.1460-9568.2006.04871.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  11 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 2.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

Review 3.  Drug targeting of dysregulated transcription in Huntington's disease.

Authors:  Aleksey G Kazantsev; Steven M Hersch
Journal:  Prog Neurobiol       Date:  2007-02-23       Impact factor: 11.685

4.  The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology.

Authors:  Joost Schulte; J Troy Littleton
Journal:  Curr Trends Neurol       Date:  2011-01-01

5.  CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease.

Authors:  Jill R Crittenden; Denise E Dunn; Farhan I Merali; Ben Woodman; Michael Yim; Anna E Borkowska; Matthew P Frosch; Gillian P Bates; David E Housman; Donald C Lo; Ann M Graybiel
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

6.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

Review 7.  Transcriptional signatures in Huntington's disease.

Authors:  Jang-Ho J Cha
Journal:  Prog Neurobiol       Date:  2007-04-01       Impact factor: 11.685

8.  Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.

Authors:  Caroline L Benn; Tingting Sun; Ghazaleh Sadri-Vakili; Karen N McFarland; Derek P DiRocco; George J Yohrling; Timothy W Clark; Bérengère Bouzou; Jang-Ho J Cha
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

Review 9.  Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis.

Authors:  Amit Kumar; Manisha Vaish; Rajiv R Ratan
Journal:  Drug Discov Today       Date:  2014-03-21       Impact factor: 7.851

10.  Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse.

Authors:  Jan Fahrenkrug; Natalija Popovic; Birgitte Georg; Patrik Brundin; Jens Hannibal
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.